Bharat Kumar1, Sohaib Aleem2, Hana Saleh3, Jennifer Petts4, Zuhair K Ballas5,6. 1. Division of Immunology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA, 52242, USA. Bharat-Kumar@UIowa.edu. 2. South Bend Clinic, South Bend, IN, USA. 3. Apex Medical Center, Hemet, CA, USA. 4. Iowa Clinic, Des Moines, IA, USA. 5. Division of Immunology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA, 52242, USA. 6. Iowa City Veterans Affairs Medical Center, Iowa City, IA, USA.
Abstract
OBJECTIVE: We assessed the clinical features and outcomes based on therapeutic options adopted during hospital stay for adult patients with macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis (MAS/sHLH). METHODS: We conducted a retrospective chart review of all adult patients (age ≥ 18 years) diagnosed with MAS/sHLH at our center between 2010 and 2015. Inclusion criteria for patients were diagnosis of MAS/sHLH during admission and patients meeting at least 5 out of 8 of Henter's criteria or at least 4 out of 6 of the criteria that were tested. RESULTS: Nineteen adult patients with MAS/sHLH met the inclusion criteria from January 2010 to October 2015 (median age 48 years; female 68.4%). Treatment had been personalized, depending on the clinical presentation and course of disease. Majority of the patients received anakinra, cyclosporine, intravenous immunoglobulins (IVIG), and steroids. Fourteen (74%) patients survived, with clinical improvement by the time of discharge. After excluding the three patients with underlying leukemia/lymphoma who opted for palliative care and subsequently died, the survival rate was 88%. CONCLUSION: A modified diagnostic and treatment protocol for adult patients with MAS/sHLH that incorporated graded introduction of medications based on clinical presentation and cytokine profile resulted in the best adult survival rate reported in literature.
OBJECTIVE: We assessed the clinical features and outcomes based on therapeutic options adopted during hospital stay for adult patients with macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis (MAS/sHLH). METHODS: We conducted a retrospective chart review of all adult patients (age ≥ 18 years) diagnosed with MAS/sHLH at our center between 2010 and 2015. Inclusion criteria for patients were diagnosis of MAS/sHLH during admission and patients meeting at least 5 out of 8 of Henter's criteria or at least 4 out of 6 of the criteria that were tested. RESULTS: Nineteen adult patients with MAS/sHLH met the inclusion criteria from January 2010 to October 2015 (median age 48 years; female 68.4%). Treatment had been personalized, depending on the clinical presentation and course of disease. Majority of the patients received anakinra, cyclosporine, intravenous immunoglobulins (IVIG), and steroids. Fourteen (74%) patients survived, with clinical improvement by the time of discharge. After excluding the three patients with underlying leukemia/lymphoma who opted for palliative care and subsequently died, the survival rate was 88%. CONCLUSION: A modified diagnostic and treatment protocol for adult patients with MAS/sHLH that incorporated graded introduction of medications based on clinical presentation and cytokine profile resulted in the best adult survival rate reported in literature.
Authors: Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka Journal: Pediatr Blood Cancer Date: 2007-02 Impact factor: 3.167
Authors: Edward M Behrens; Scott W Canna; Katharine Slade; Sheila Rao; Portia A Kreiger; Michele Paessler; Taku Kambayashi; Gary A Koretzky Journal: J Clin Invest Date: 2011-05-16 Impact factor: 14.808
Authors: David T Teachey; Susan R Rheingold; Shannon L Maude; Gerhard Zugmaier; David M Barrett; Alix E Seif; Kim E Nichols; Erica K Suppa; Michael Kalos; Robert A Berg; Julie C Fitzgerald; Richard Aplenc; Lia Gore; Stephan A Grupp Journal: Blood Date: 2013-05-15 Impact factor: 22.113
Authors: Nicholas Hartog; William Faber; Austin Frisch; Jacob Bauss; Caleb P Bupp; Surender Rajasekaran; Jeremy W Prokop Journal: Expert Rev Proteomics Date: 2021-04-05 Impact factor: 3.940
Authors: Luis M Amezcua-Guerra; Karen Audelo; Juan Guzmán; Diana Santiago; Julieta González-Flores; Carlos García-Ávila; Zaira Torres; Francisco Baranda-Tovar; Claudia Tavera-Alonso; Julio Sandoval; Héctor González-Pacheco Journal: Inflamm Res Date: 2021-05-10 Impact factor: 4.575
Authors: L Suárez-Hormiga; M N Jaén-Sánchez; E A Verdugo-Espinosa; C Carranza-Rodríguez; P M Hernández-Cabrera; E Pisos-Álamo; A Francés-Urmeneta; J L Pérez-Arellano Journal: Rev Esp Quimioter Date: 2020-06-19 Impact factor: 1.553
Authors: Ana Copaescu; Olivia Smibert; Andrew Gibson; Elizabeth J Phillips; Jason A Trubiano Journal: J Allergy Clin Immunol Date: 2020-09 Impact factor: 10.793
Authors: Lauren A Henderson; Scott W Canna; Grant S Schulert; Stefano Volpi; Pui Y Lee; Kate F Kernan; Roberto Caricchio; Shawn Mahmud; Melissa M Hazen; Olha Halyabar; Kacie J Hoyt; Joseph Han; Alexei A Grom; Marco Gattorno; Angelo Ravelli; Fabrizio De Benedetti; Edward M Behrens; Randy Q Cron; Peter A Nigrovic Journal: Arthritis Rheumatol Date: 2020-05-10 Impact factor: 15.483